Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 34894129.
- Also identified by DOI 10.1093/cid/ciab1015 and PMC identifier 9410717.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Exebacase, an antistaphylococcal lysin produced from a bacteriophage-encoded gene, is a promising adjunctive therapy for severe methicillin-resistant Staphylococcus aureus infections. We describe the first infant to receive exebacase, dosing, and pharmacokinetics. Exebacase may be safe and efficacious in children; however, further clinical trials are needed to optimize dosing.
Medical subject headings
- Methicillin-Resistant Staphylococcus aureus
- Staphylococcal Infections